Parkinson's disease (PD) is a progressive neurological disorder characterized by a large number of motor and non-motor features. Fatigue is one of the most common and most disabling symptoms among patients with PD, and it has a significant impact on their quality of life. Although fatigue has been recognized for a long time, its pathophysiology remains poorly understood, and there is no evidence to support any therapeutic approach in PD patients. Expert consensus on case definition and diagnostic criteria for PD-related fatigue have been recently published, and although they still need to be adequately validated, they provide a great step forward in the study of fatigue. The goal of this article is to provide relevant information for the identification and management of patients with fatigue.
INTRODUCTION
Parkinson's disease (PD) is a progressive disorder that manifests itself clinically through motor and nonmotor symptoms with varying degrees of disability. 1 It is the second most common neurodegenerative disease and the main cause of parkinsonism. 2 A frequent clinical condition in the elderly, PD affects approximately 1% of the population over 65 years. 3 The cardinal motor manifestations of PD include bradykinesia, resting tremor, rigidity, and postural instability, all of which are related to the degeneration of dopaminergic neurons in the pars compacta of the substantia nigra and the reduction in striatal dopamine. 3, 4 Although a diagnosis of PD is usually confirmed at the onset of motor manifestations, these findings can be preceded, for 20 years or more, by non-motor manifestations such as olfactory impairment, constipation, rapid eye movement sleep behavioural disorder, depression, and excessive daytime sleepiness (EDS). Cognitive impairment, psychiatric symptoms, autonomic disorders, pain, and fatigue may be part of the symptomatology. 2, 4 In the last two decades, these non-motor symptoms, including fatigue, have drawn the attention of clinical research, which traditionally focused only on the motor aspects of the disease. However, this unexplored area likely influences motor performance and activities of daily living. Therefore, with the aim of updating and verifying the effects of PD's nonmotor symptomatology, we performed a literature review by searching for published articles about fatigue in PD in recent years.
METHODS
A review of the literature was conducted by searching the PubMed database using the term 'Parkinson's disease' associated with one of the following terms: 'fatigue', 'apathy', 'depression', and 'excessive daytime sleepiness'. We excluded articles with unclear or inconclusive methodology or results, those considered not relevant to the proposed topic, and those that did not have the full text available online. Emphasis was given to more recent work (last 5 years). However, older articles of high relevance, such as population studies involving large numbers of participants and those with historical significance, were included.
Among patients with neurological diseases, the prevalence of fatigue is particularly common in multiple sclerosis, PD, amyotrophic lateral sclerosis, traumatic brain injury, stroke, and myasthenia gravis. 6 Around 40% of multiple sclerosis patients and up to onethird of PD patients report fatigue as the most disabling symptom, 7, 8 which shows the importance of recognizing the role of this symptom. However, its clinical identification and relation with the underlying disease can be difficult at times because fatigue can be associated or even caused by neuropsychiatric disorders, such as depression, anxiety, and apathy. 9 'Fatigue' is a term widely used in clinical practice, and health professionals must have the knowledge to identify and evaluate the complaint. Although it may be a normal response to exercise or stress, it can also be a sign of some diseases. 6 In this sense, fatigue can be considered physiological or pathological. 10 In healthy individuals, fatigue is a physiological reaction to intense and prolonged activity; it is predictable and transient and can be relieved with rest without compromising daily activities. 6 In patients with pathological fatigue, the characterization is distinct, 6 with fatigue involving feelings of tiredness at rest, a lack of energy that compromises daily activities, or even loss of vigour. 11 Jason et al. defined fatigue as pathological when it has a duration of more than 3 months, is more intense than previously experienced fatigue, and compromises daily activities and quality of life. 12 Fatigue may last for more than 6 months (chronic fatigue) and may be associated with emotional or social disorders. 13, 14 Fatigue can be categorized as peripheral or central. 15 Peripheral fatigue (objective or fatigability)
represents loss of muscle strength caused by repeated contractions. Central (subjective) fatigue is a perception described as a feeling of tiredness, weakness, or exhaustion that involves physical and/or mental domains; 16, 17 this type of fatigue can be mental or physical. 18 Physical fatigue involves a sense of physical exhaustion and a lack of energy to perform tasks despite the ability and motivation to perform them. Mental fatigue refers to cognitive effects experienced during and after prolonged periods of activity involving cognitive demand and tasks that require sustained attention and mental endurance. 19 Despite fatigue's apparent epidemiological importance, many fundamental questions remain unanswered, such as its definition. 20 Even among studies that define fatigue there are considerable controversies. 21 A suggested definition for subjective fatigue is 'a feeling of exhaustion not explained by drug effects or other clinical or psychiatric conditions present for a defined period and associated with other fatigue-related symptoms such as reduced motivation and non-restorative rest or activity restriction'. 10 The definition can also be based on aspects related to this symptom, such as the distinction between fatigue and related disorders (e.g. depression, apathy and EDS), between fatigue and fatigability, and between pathological and physiological fatigue; alternatively, the definition may be based on identification of the causal factor and specification of the affected domain.
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EPIDEMIOLOGY
The prevalence of fatigue in PD varies between 33% and 70%. 10 This broad range probably reflects different patient populations and different evaluation methodologies. The first reference to fatigue associated with PD was from 1967. 22 In 1993, two studies showed a higher prevalence of fatigue in PD patients than in controls and considered fatigue as one of the non-motor symptoms of the disease. The first study demonstrated the prevalence of excessive fatigue as determined by a pre-established scale in almost 50% of the patients. 23 The second study, in which there were more PD patients than controls with depression and fatigue, found that fatigue was present in nondepressed patients-that is, it was an independent symptom. In this study, almost one-third of the subjects considered fatigue as their most disabling symptom. 8 A study by van Hilten et al. showed that the prevalence of fatigue was greater than 40% in PD patients and was considered the worst PD symptom by 15% and the least severe by 31%. 24 A Brazilian study found that fatigue was present in 70% of 50 PD patients, 25 indicating the prevalence and importance of this symptom. The same occurred in a later British study, in which fatigue was the second most common non-motor symptom. 26 Multicentric studies such as PRIAMO and ELLDOPA had similar results. In the PRIAMO study, fatigue was considered the most common non-motor symptom among the 1072 patients evaluated. 27 The ELLDOPA study, which involved patients with a recent PD diagnosis D. V. Nassif and J. S. Pereira who had not received treatment, showed that fatigue is an early symptom that affects around one-third of these patients. 28 
PRIMARY AND SECONDARY FATIGUE: CONFOUNDING FACTORS
A study evaluating the presence of various nonmotor symptoms such as fatigue, anxiety, EDS, depression, and sensory symptoms through clinical scales showed that 59% of the patients had two or more of these symptoms and almost 25% had four or more. 29 Thus, fatigue may be associated with other non-motor symptoms, like depression, apathy, and sleepiness, which can act as confounding factors and make diagnosis difficult. Recent findings suggest that fatigue may be related to cognitive impairment. 30, 31 In view of this, the concepts of primary fatigue and secondary fatigue were proposed based on their association with neuropsychiatric disorders, such as mood disorders, apathy, and EDS. Most evidence suggests that fatigue is a primary manifestation of PD rather than secondary to another disorder. 29 Fatigue and sleep Among the factors that may confound the diagnosis of fatigue are symptoms related to sleep disorders, which affect more than 75% of PD patients. 32 In particular, EDS, which is present in 8-50% of patients, 33 may worsen with disease progression. 34 In a study of 88 patients, Valko et al. observed that the prevalence of fatigue was 59%, EDS was 48%, and presence of the two associated symptoms was 35%. 35 PD patients with severe sleep disturbances tend to suffer from fatigue. 36 In cases of suspicious sleep disorders, we may seek diagnosis through clinical history, appropriate scales, and/or neurophysiological methods. 37 It is important for health professionals to understand that fatigue and sleepiness are not synonymous, as some studies have demonstrated, but they act as factors of uncertainty in the diagnosis. 18 Alves et al. showed that fatigue may be related to other non-motor symptoms, such as depression and EDS, but these are not always associated; moreover, fatigue may occur in isolation. 38 In one study the presence of significant fatigue (defined as 16-item Parkinson's Fatigue Scale ≥3.3) was associated with a higher prevalence of sleep disorders. 39 Patients with fatigue remained fatigued even after napping, which was not the case with sleepy patients who felt better. 33 Fatigue and depression Depression and other mood disorders are very common in PD and affect approximately 50% of patients. 40 Depression may occur at any time during the course of PD, 41 and its diagnosis is made based on the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, criteria. 42 Fatigue is part of the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, diagnostic criteria for depression and anxiety, both of which are common disorders in PD that may be associated with fatigue; as such, these disorders can be confounding factors in the identification of fatigue. 18 Friedman and Friedman observed that fatigue may correlate with depression but found that these symptoms are independent. 8 Another study demonstrated a higher prevalence of depression, anxiety, and autonomic dysfunction in fatigued patients. 43 The presence of fatigue in patients without depression was demonstrated by van Hilten et al. 24 These studies supported the idea that fatigue is an independent symptom of depression. About 35% of depressive patients present residual fatigue even after successful treatment of depressive symptoms. 44 Fatigue and apathy Apathy can be defined as a state of decreased motivation that manifests as a decrease in goaldirected behaviours; it can be variably characterized by reduced interests or emotions that cannot be attributed to a diminished level of consciousness, cognitive impairment, or emotional distress. 45 Apathy can be erroneously interpreted as fatigue in PD patients. 45 Its prevalence in PD patients ranges from 17% to 50%. 46 Apathy may also be associated with depression. 47 Skorvanek et al. evaluated 151 non-PD patients through clinical scales and observed that the prevalence and severity of fatigue and apathy were higher in depressed patients. However, fatigue, depression, and apathy may be independent symptoms. 48 Cochrane et al. evaluated the relationship between fatigue and apathy and observed that most fatigued PD patients were also apathetic. 49 A study of patients with early treatment-naïve PD revealed that among non-motor Fatigue in Parkinson's disease symptoms, the presence of apathy had greater association with fatigue and anhedonia 50 .
MEASURING FATIGUE
Fatigue is usually measured through scales because there are no specific biomarkers. 18 In 2010, the Movement Disorders Society task force evaluated clinical scales for subjective fatigue rating and assessed their psychometric and clinical properties, as well as the evidence to support the use of these scales in clinical studies of PD.
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Depending on the quality of the data, the scales were classified as 'recommended', 'suggested', or 'listed'. The Fatigue Severity Scale (FSS) is the most commonly used scale to assess the conditions associated with fatigue. 51 It was the only scale among those evaluated to receive the 'recommended' classification of the Movement Disorders Society task force for both screening and grading the severity of fatigue. 52 The Multidimensional
Fatigue Inventory was classified as 'suggested' for screening and 'recommended' for grading the degree of severity. 53 It may be more sensitive than the FSS to changes associated with intervention. Another advantage of the Multidimensional Fatigue Inventory is that it is evaluates five dimensions of fatigue (i.e. general, physical, mental, reduced activity, and reduced motivation). 54 For screening for fatigue, two other scales were classified as 'recommended': the Functional Assessment of Chronic Illness Therapy-Fatigue Scale and Parkinson Fatigue Scale. 55, 56 The latter scale is the only one specifically designed to assess fatigue in PD, but it does not seem to be more useful than the others. 18 These scales measure subjective fatigue associated with PD. Objective fatigue (fatigability) refers to a measurable decline in performance during a sustained task 20 . Subjective fatigue and fatigability are distinct and independent concepts. In patients with PD, Lou et al. demonstrated that an objective reduction in motor performance does not always correlate with subjective fatigue. 57 Fatigability can be measured in PD based on performance change during sustained muscle contraction, repetition of movements, or timed activities. 10 Fatigue can also be induced by cognitive tasks. 52 
PHYSIOPATHOLOGY
Although there is information about muscle fatigue, little is known about the pathophysiology of central fatigue associated with PD. 33 Most of the evidence suggests that fatigue is a symptom intrinsic to the pathological substrates associated with PD-that is, it is a primary manifestation and not secondary to mood disorders, sleep disorders, or medications. 15 Several theories have been proposed. Inflammatory markers such as C-reactive protein and cytokines are potential biomarkers for subjective fatigue. 10 Lindqvist et al. quantified the cerebrospinal fluid levels of inflammatory markers in patients with PD and in a control group. 58 Elevated levels of these inflammatory markers were associated with more severe symptoms of depression, fatigue, and cognitive impairment. Another study showed that PD patients with fatigue have higher levels of interleukin-6 than those without. 59 In addition, neuroinflammatory and autoimmune diseases, which are known to be associated with elevated levels of cytokines, are also associated with fatigue. 60 Other suggested pathophysiological mechanisms include dysfunction of the hypothalamic-pituitaryadrenal system or testosterone levels. Chaudhuri and Behan described dysfunction of the hypothalamic adrenal axis, in addition to changes in cytokine levels and the circuit associated with basal ganglia, as a mechanism associated with fatigue. 17 Kluger et al.
suggested that despite the possible association between fatigue and hypothalamic lesions, the causative mechanism may not be a direct insult to this structure, as these patients may also present with endocrine and circadian rhythm disorders, which function as confounding factors. 20 Kenangil et al. investigated the relationship between testosterone levels, fatigue, and apathy in male PD patients and concluded that although these patients had lower levels of free testosterone than the control group, there was no correlation with fatigue severity score. 61 In a doublemasked, parallel group, and placebo-controlled trial, Okun et al. evaluated the effect of testosterone therapy on motor and non-motor symptoms, including fatigue, in men with PD and a free testosterone level less than 100 pg/mL. 62 No significant changes between the groups were observed based on the subscales of the Multidimensional Fatigue Inventory. Some studies with neuroimaging were performed in an attempt to provide pathological substrates. Abe D. V. Nassif and J. S. Pereira et al. evaluated 26 PD patients and 26 control patients after they underwent single-photon emission computed tomography with technetium-99 hexamethylpropyleneamineoxime and were administered fatigue and depression scales. 63 They observed a significant correlation between the presence of fatigue and reduced perfusion in the frontal lobe in PD patients. Pavese et al. used positron emission tomography with dopaminergic and serotonergic markers to investigate possible dysfunction of these neurotransmitters in the limbic circuit and basal ganglia in PD patients with fatigue, but without history of depression or sleep disorders, and PD patients without fatigue. 64 Compared to the nonfatigued patients, the PD patients with fatigue had significantly less serotonergic marker binding in the putamen, caudate nucleus, ventral striatum, and thalamus, as well as in the anterior cingulate, amygdala, and insular regions. The uptake of the dopaminergic marker was similar in both groups but was reduced in the caudate and insula in the fatigued group. The authors concluded that fatigue in PD is associated with a reduction in serotonergic function in the basal ganglia and limbic structures; they also found that insular dopaminergic dysfunction may play a role in the pathophysiology of this disorder. Using restingstate functional magnetic resonance imaging, Tessitore et al. demonstrated that distressing fatigue in drug-naïve patients with early PD is associated with a decreased connectivity within the supplementary motor area and an increased connectivity within the prefrontal and posterior cingulate cortices within the default mode network. 65 The authors hypothesized that these divergent motor and cognitive network connectivity changes and their adaptive or maladaptive functional outcomes may play a prominent role in the pathophysiology of fatigue in PD.
APPROACH TO PATIENTS WITH PD AND FATIGUE AND CASE DEFINITION
Fatigue has a high prevalence among PD patients and greatly affects their quality of life; as such, health-care professionals should always determine if fatigue is present in PD patients. There are several confounding factors to consider when addressing a fatigue complaint. For example, patient may not recognize that they are fatigued. Recently, Kluger et al.
proposed diagnostic criteria for PD-related fatigue. 52 They suggested that patients should report significantly reduced energy levels or increased perceptions of effort that are disproportionate to attempted activities or general activity level. The symptoms must be present for most of the day, (nearly) every day during the previous month. Four of the following characteristics should be present: (i) symptoms are induced by activities of day living; (ii) symptoms occur with little or no exertion; (iii) symptoms limit the type, intensity, and duration of activities performed; (iv) Symptoms are not reliably relieved by rest or may require prolonged periods of rest; (v) symptoms are brought on by cognitive tasks or situations requiring sustained attention, including social interactions; (vi) vigorous activities are avoided for fear of worsening symptoms; (vii) mild to moderate exertion worsens symptoms for hours to days; (viii) symptoms have a predictable diurnal pattern regardless of the activities performed; and (ix) symptoms are unpredictable and may have a sudden onset. Due to fatigue, the patient must have significant clinical impairment or impairment in social, occupational, or other important areas. Secondary causes should be ruled out based on evidence from the patient's history and physical examination to determine whether fatigue is a consequence of PD. However, we believe that these criteria were based on indirect evidence and expert opinions, and therefore require validation. The distinction between primary and secondary fatigue is important. It should be borne in mind that fatigue is not always associated with PD, and other conditions may be responsible for the symptom; it is difficult to differentiate fatigue due to PD from fatigue due to psychiatric or clinical disorders. Several causes are associated with fatigue, including chronic pain, respiratory and cardiac dysfunction, malignancies, and hepatic, haematological, rheumatologic, and neurological disorders. 6, 20 Neuropsychiatric conditions with a high prevalence of PD, such as depression, apathy, and EDS, should be differentiated from fatigue. 20 Medications, such as beta-blockers, antihistamines, muscle relaxants, benzodiazepines, sleep inducers, and some antidepressants (e.g. serotonin receptor blockers and serotonin-norepinephrine receptor blockers), are also associated with fatigue. 66 Laboratory tests, including complete blood count, erythrocyte sedimentation rate, C-reactive protein, electrolytes, and renal, hepatic and thyroid functions, may be requested to identify secondary causes.
Serologies for HIV and hepatitis C infection may be requested, as well as other tests, to determine a specific aetiological diagnosis. 66 
TREATMENT
The first and most important step in dealing with PD patients with fatigue is to explain to them and their family that this is an important and common symptom of PD. They must also be made aware that this is a symptom that unfortunately cannot be treated effectively. Fatigue management is symptomatic, and several pharmacological and non-pharmacological treatments have been studied. In the ELLDOPA trial, levodopa-naïve individuals with early PD were enrolled and assigned to receive placebo or carbidopa-levodopa for 40 weeks, followed by a 2-week medication washout period. Subjects who scored >4 on the FSS were classified as fatigued. Although FSS scores increased in all ELLDOPA treatment groups from baseline to week 40, this increase was greater in the placebo group than in the levodopa groups; however, this difference did not reach significance (P = 0.086). A greater increase in fatigue score was observed from baseline to the end of the 2-week washout in the placebo group, compared to the three groups receiving levodopa (P = 0.031). This indicated that there was less progression of fatigue in the patient groups treated with levodopa. 28 Lou et al. observed a reduction in physical fatigue as measured through finger tapping and force generation in patients using levodopa. 57 However, there has been no consistent evidence regarding the benefit of levodopa for fatigue. 67 The effects of dopaminergic agonists on fatigue are uncertain, and fatigue may even be an adverse effect of this type of medication. 68 However, one study showed that treatment-naïve patients had lower levels of fatigue after 1 year of treatment and that patients using dopaminergic agonists had greater benefit than those taking levodopa. 69 In a study evaluating the effect of rasagiline on fatigue, patients who received 1mg per day of the medication had lower levels of fatigue than those the placebo group at the end of 12 weeks. 70 In a substudy of ADAGIO, 71 patients receiving placebo, rasagiline 1mg per day, and rasagiline 2 mg per day were administered the Parkinson Fatigue Scale at baseline and at the end of 36 weeks. ) and medications such as tricyclic antidepressants and memantine, 75, 76 but these do not appear to be effective. 67 Additionally, although amantadine is used in other neurological disorders to treat fatigue, there is still a lack of studies on its use in fatigue associated with PD. However, in a trial, amantadine was not associated with improvement in general fatigue in patients with PD. 77 Little is known about the effects of deep brain stimulation (DBS) on fatigue. 15 Motor function in PD has a good response to bilateral subthalamic nucleus DBS, but its effect on fatigue remains unknown. In one study, patients with PD who underwent subthalamic nucleus DBS did not have any evident changes in fatigue severity, but changes in the degree of individual fatigue impairment were observed. These changes were related to the effect of subthalamic nucleus DBS on motor function and mood. 78 However, in another study, it was observed that fatigue may occur frequently after DBS in PD and negatively affect the quality of life of these patients. 79 Unfortunately, studies involving other non-pharmacological interventions in patients with fatigue and PD are scarce. 67 There are no specific guidelines for the management of fatigue associated with PD, and several studies concluded that there is insufficient evidence to apply pharmacological and non-pharmacological therapies. 67, 80, 81 
CONCLUSIONS
Despite of the high prevalence of fatigue and the great impact on the quality of life of PD patients, the development of the topic remains compromised by a lack of recognition by health professionals and the absence of basic concepts such as definition and pathophysiology. Despite the therapeutic limitation, fatigue should be recognized and the complaint should be valued. A more accurate evaluation of this disorder, identifying the main symptoms that act as confounding factors, such as apathy, depression and EDS, as well as of treatable causes can change the final outcome, providing a better interpretation and a clearer clinical vision on these frequent complaints of PD patients, providing subsidies for diagnosis and appropriate treatment.
